An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients
- PMID: 32328562
- PMCID: PMC7165803
- DOI: 10.1093/jncics/pkz094
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients
Abstract
Background: NUT midline carcinoma, renamed NUT carcinoma (NC), is an aggressive squamous cancer defined by rearrangement of the NUTM1 gene. Although a subset of patients can be cured, for the majority of patients the prognosis is grim. We sought to classify patients into risk groups based on molecular and clinicopathologic factors at the time of diagnosis.
Methods: Clinicopathologic variables and survival outcomes were extracted for a total of 141 NC patients from the NUT midline carcinoma Registry using questionnaires and medical records. Translocation type was identified by molecular analyses. Survival tree regression analysis was performed to determine risk factors associated with overall survival (OS).
Results: For 141 patients, the median age at diagnosis was 23.6 years. Fifty-one percent had thoracic origin compared with 49% nonthoracic sites (41% head and neck, 6% bone or soft tissue, 1% other). The median OS was 6.5 months (95% confidence interval [CI] = 5.8 to 9.1 months). Most patients had the BRD4-NUTM1 fusion (78%), followed by BRD3-NUTM1 (15%) and NSD3-NUTM1 (6%). Survival tree regression identified three statistically distinct risk groups among 124 patients classified by anatomical site and genetics: group A is nonthoracic primary, BRD3-, or NSD3-NUT (n = 12, median OS = 36.5 months, 95% CI = 12.5 to not reported months); group B is nonthoracic primary, BRD4-NUT (n = 45, median OS = 10 months, 95% CI = 7 to 14.6 months); and group C is thoracic primary (n = 67, median OS = 4.4 months, 95% CI = 3.5 to 5.6 months). Only groups A and B had long-term (≥3 years, n = 12) survivors.
Conclusions: We identify three risk groups defined by anatomic site and NUT fusion type. Nonthoracic primary with non-BRD4-NUT fusion confers the best prognosis, followed by nonthoracic primary with BRD4-NUT. Thoracic NC patients, regardless of the NUT fusion, have the worst survival.
© The Author(s) 2019. Published by Oxford University Press.
Figures
Similar articles
-
NUT carcinoma, an under-recognized malignancy: a clinicopathologic and molecular series of 6 cases showing a subset of patients with better prognosis and a rare ZNF532::NUTM1 fusion.Hum Pathol. 2022 Aug;126:87-99. doi: 10.1016/j.humpath.2022.05.015. Epub 2022 May 24. Hum Pathol. 2022. PMID: 35623465
-
NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics.Front Oncol. 2022 Mar 16;12:860830. doi: 10.3389/fonc.2022.860830. eCollection 2022. Front Oncol. 2022. PMID: 35372003 Free PMC article. Review.
-
BRD3-NUTM1-expressing NUT carcinoma of lung on endobronchial ultrasound-guided transbronchial needle aspiration cytology, a diagnostic pitfall.Diagn Cytopathol. 2022 Feb;50(2):E47-E53. doi: 10.1002/dc.24885. Epub 2021 Oct 21. Diagn Cytopathol. 2022. PMID: 34672128
-
Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.Cancer. 2016 Dec 1;122(23):3632-3640. doi: 10.1002/cncr.30242. Epub 2016 Aug 10. Cancer. 2016. PMID: 27509377 Free PMC article.
-
NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.Pathol Int. 2018 Nov;68(11):583-595. doi: 10.1111/pin.12727. Epub 2018 Oct 26. Pathol Int. 2018. PMID: 30362654 Review.
Cited by
-
Suspected NUT carcinoma progressing on pembrolizumab, carboplatin, and paclitaxel as first-line treatment: a case report.Ann Med Surg (Lond). 2023 Dec 2;86(2):1061-1065. doi: 10.1097/MS9.0000000000001501. eCollection 2024 Feb. Ann Med Surg (Lond). 2023. PMID: 38333300 Free PMC article.
-
Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma.J Immunother Precis Oncol. 2024 Feb 5;7(1):67-72. doi: 10.36401/JIPO-23-19. eCollection 2024 Feb. J Immunother Precis Oncol. 2024. PMID: 38327754 Free PMC article.
-
Neuroendocrine and squamous cell phenotypes of NUT carcinoma are potential diagnostic pitfalls that discriminating it from mimickers, such as small cell and squamous cell carcinoma.Diagn Pathol. 2024 Feb 7;19(1):27. doi: 10.1186/s13000-024-01448-7. Diagn Pathol. 2024. PMID: 38326851 Free PMC article.
-
Case report: Diagnosis of NUT carcinoma of hepatic origin by next-generation sequencing.Front Oncol. 2024 Jan 23;13:1304457. doi: 10.3389/fonc.2023.1304457. eCollection 2023. Front Oncol. 2024. PMID: 38322288 Free PMC article.
-
Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report.JTO Clin Res Rep. 2023 Dec 23;5(1):100625. doi: 10.1016/j.jtocrr.2023.100625. eCollection 2024 Jan. JTO Clin Res Rep. 2023. PMID: 38287941 Free PMC article.
References
-
- French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA.. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63(2):304–307. - PubMed
-
- French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol. 2004;22(20):4135–4139. - PubMed
-
- French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27(15):2237–2242. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources